Avadel Long Term Debt Total vs Intangible Assets Analysis
AVDL Stock | USD 15.75 0.13 0.83% |
Avadel Pharmaceuticals financial indicator trend analysis is way more than just evaluating Avadel Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Avadel Pharmaceuticals is a good investment. Please check the relationship between Avadel Pharmaceuticals Long Term Debt Total and its Intangible Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Long Term Debt Total vs Intangible Assets
Long Term Debt Total vs Intangible Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Avadel Pharmaceuticals Long Term Debt Total account and Intangible Assets. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Avadel Pharmaceuticals' Long Term Debt Total and Intangible Assets is -0.67. Overlapping area represents the amount of variation of Long Term Debt Total that can explain the historical movement of Intangible Assets in the same time period over historical financial statements of Avadel Pharmaceuticals PLC, assuming nothing else is changed. The correlation between historical values of Avadel Pharmaceuticals' Long Term Debt Total and Intangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt Total of Avadel Pharmaceuticals PLC are associated (or correlated) with its Intangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Intangible Assets has no effect on the direction of Long Term Debt Total i.e., Avadel Pharmaceuticals' Long Term Debt Total and Intangible Assets go up and down completely randomly.
Correlation Coefficient | -0.67 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Long Term Debt Total
Intangible Assets
Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.Most indicators from Avadel Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Avadel Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. At this time, Avadel Pharmaceuticals' Selling General Administrative is quite stable compared to the past year. Issuance Of Capital Stock is expected to rise to about 153.4 M this year, although the value of Discontinued Operations will most likely fall to about 4.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 9.9M | 12.3M | 9.9M | 10.4M | Depreciation And Amortization | 979K | 4.8M | 1.8M | 1.7M |
Avadel Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Avadel Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Avadel Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 151.4M | 311.6M | 247.3M | 132.8M | 261.1M | 138.0M | |
Short Long Term Debt Total | 124.7M | 130.5M | 145.0M | 131.0M | 35.4M | 38.3M | |
Other Current Liab | 3.9M | 5.2M | 5.3M | 9.3M | 24.5M | 15.3M | |
Total Current Liabilities | 36.0M | 15.1M | 21M | 55.8M | 36.9M | 29.7M | |
Total Stockholder Equity | (29.2M) | 162.3M | 78.2M | (21.1M) | 87.7M | 47.1M | |
Property Plant And Equipment Net | 4.2M | 3.0M | 2.9M | 2.6M | 3.2M | 3.0M | |
Net Debt | 114.9M | 58.8M | 94.3M | 57.0M | 4.2M | 4.0M | |
Retained Earnings | (391.2M) | (384.2M) | (447.8M) | (585.2M) | (745.5M) | (708.2M) | |
Accounts Payable | 6.1M | 2.9M | 7.7M | 7.9M | 11.4M | 6.3M | |
Cash | 9.8M | 71.7M | 50.7M | 74.0M | 31.2M | 28.3M | |
Non Current Assets Total | 69.1M | 48.2M | 54.8M | 31.9M | 126.9M | 133.3M | |
Non Currrent Assets Other | 39.3M | 24.9M | 33.8M | (60.0M) | 10.2M | 7.4M | |
Cash And Short Term Investments | 64.2M | 221.4M | 157.2M | 96.5M | 105.1M | 72.6M | |
Net Receivables | 10.4M | 3.3M | 2.4M | 2.2M | 13.4M | 9.7M | |
Common Stock Shares Outstanding | 37.4M | 54.9M | 58.5M | 60.1M | 80.2M | 84.2M | |
Liabilities And Stockholders Equity | 151.4M | 311.6M | 247.3M | 132.8M | 261.1M | 138.0M | |
Non Current Liabilities Total | 144.7M | 134.3M | 148.0M | 98.1M | 136.5M | 143.4M | |
Inventory | 6.2M | 4.8M | 3.6M | 0.0 | 10.4M | 10.9M | |
Other Current Assets | 4.3M | 38.7M | 32.8M | 2.1M | 5.3M | 5.6M | |
Other Stockholder Equity | 384.4M | 566.9M | 549.3M | 589.8M | 855.5M | 898.2M | |
Total Liab | 180.6M | 149.4M | 169.0M | 153.9M | 173.4M | 90.9M | |
Property Plant And Equipment Gross | 10.6M | 8.2M | 2.9M | 2.6M | 14.0M | 12.4M | |
Total Current Assets | 82.4M | 263.5M | 192.5M | 100.8M | 134.2M | 91.1M | |
Accumulated Other Comprehensive Income | (22.8M) | (21.1M) | (23.9M) | (26.3M) | (23.2M) | (22.0M) | |
Short Term Debt | 645K | 474K | 900K | 38.6M | 934K | 887.3K | |
Common Stock Total Equity | 427K | 429K | 583K | 586K | 527.4K | 501.0K | |
Common Stock | 429K | 583K | 586K | 628K | 898K | 853.1K | |
Other Liab | 20.6M | 4.2M | 3.9M | 5.7M | 6.6M | 6.3M | |
Current Deferred Revenue | 114K | 25.4M | 6.5M | 7.2M | 8.2M | 4.2M | |
Other Assets | 39.2M | 28.4M | 35.0M | 12.6M | 14.4M | 10.2M | |
Long Term Debt | 121.7M | 128.2M | 142.4M | 91.6M | 105.4M | 110.6M | |
Property Plant Equipment | 544K | 359K | 285K | 2.6M | 2.3M | 2.2M | |
Short Term Investments | 54.4M | 149.7M | 106.5M | 22.5M | 73.9M | 64.8M | |
Net Tangible Assets | (48.5M) | 145.4M | 61.4M | (38.0M) | (43.7M) | (41.5M) | |
Retained Earnings Total Equity | (358.0M) | (391.2M) | (384.2M) | (447.8M) | (403.0M) | (423.1M) | |
Long Term Debt Total | 115.7M | 121.7M | 128.2M | 142.4M | 163.8M | 171.9M | |
Capital Surpluse | 433.8M | 434.4M | 566.9M | 549.3M | 631.8M | 491.4M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Avadel Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Avadel Pharmaceuticals information on this page should be used as a complementary analysis to other Avadel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Avadel Stock analysis
When running Avadel Pharmaceuticals' price analysis, check to measure Avadel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avadel Pharmaceuticals is operating at the current time. Most of Avadel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Avadel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avadel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Avadel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is Avadel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.82) | Revenue Per Share 0.633 | Quarterly Revenue Growth (1.00) | Return On Assets (0.55) | Return On Equity (7.80) |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.